Zhao, Shuang G.
Chen, William S.
Li, Haolong
Foye, Adam
Zhang, Meng
Sjöström, Martin http://orcid.org/0000-0002-2629-9966
Aggarwal, Rahul
Playdle, Denise
Liao, Arnold
Alumkal, Joshi J.
Das, Rajdeep http://orcid.org/0000-0002-1041-4931
Chou, Jonathan
Hua, Junjie T.
Barnard, Travis J.
Bailey, Adina M.
Chow, Eric D. http://orcid.org/0000-0001-8079-918X
Perry, Marc D. http://orcid.org/0000-0001-6476-2942
Dang, Ha X.
Yang, Rendong http://orcid.org/0000-0002-9512-2240
Moussavi-Baygi, Ruhollah
Zhang, Li
Alshalalfa, Mohammed
Laura Chang, S.
Houlahan, Kathleen E. http://orcid.org/0000-0002-2273-2099
Shiah, Yu-Jia
Beer, Tomasz M.
Thomas, George
Chi, Kim N.
Gleave, Martin
Zoubeidi, Amina
Reiter, Robert E.
Rettig, Matthew B.
Witte, Owen
Yvonne Kim, M.
Fong, Lawrence
Spratt, Daniel E.
Morgan, Todd M. http://orcid.org/0000-0002-1140-0603
Bose, Rohit http://orcid.org/0000-0002-6785-0697
Huang, Franklin W.
Li, Hui
Chesner, Lisa
Shenoy, Tanushree
Goodarzi, Hani http://orcid.org/0000-0002-9648-8949
Asangani, Irfan A.
Sandhu, Shahneen
Lang, Joshua M.
Mahajan, Nupam P.
Lara, Primo N.
Evans, Christopher P.
Febbo, Phillip
Batzoglou, Serafim
Knudsen, Karen E.
He, Housheng H. http://orcid.org/0000-0003-2898-3363
Huang, Jiaoti
Zwart, Wilbert
Costello, Joseph F.
Luo, Jianhua
Tomlins, Scott A.
Wyatt, Alexander W.
Dehm, Scott M. http://orcid.org/0000-0002-7827-5579
Ashworth, Alan
Gilbert, Luke A. http://orcid.org/0000-0001-5854-0825
Boutros, Paul C. http://orcid.org/0000-0003-0553-7520
Farh, Kyle http://orcid.org/0000-0001-6947-8537
Chinnaiyan, Arul M. http://orcid.org/0000-0001-8743-7480
Maher, Christopher A. http://orcid.org/0000-0002-9035-603X
Small, Eric J. http://orcid.org/0000-0003-3191-6268
Quigley, David A. http://orcid.org/0000-0002-4726-1473
Feng, Felix Y. http://orcid.org/0000-0002-0963-7687
Article History
Received: 11 January 2020
Accepted: 20 May 2020
First Online: 13 July 2020
Competing interests
: P.F., S.B., K.F. and A.L. are employees of Illumina Inc., which provided material support for this project. No other commercial entities contributed to or played a role in the writing of this article. J.M.L. holds equity in Salus Discovery, LLC. L.F. has funding from BMS, Abbvie, Janssen, Roche/Genentech and Merck. O.W. currently has consulting, equity and/or board relationships with Trethera Corporation, Kronos Biosciences, Sofie Biosciences, Breakthrough Properties, Vida Ventures, Nanmi Therapeutics and Allogene Therapeutics. The University of Michigan and Brigham and Women’s Hospital have been issued patents on ETS gene fusions in prostate cancer, on which S.A.T. is a co-inventor. The diagnostic field of use was licensed to Hologic/Gen-Probe Inc., which has sublicensed rights to Roche/Ventana Medical Systems. S.A.T. has served as a consultant for and received honoraria from Janssen, AbbVie, Sanofi, Almac Diagnostics and Astellas/Medivation. S.A.T. has sponsored research agreements with Astellas/Medivation and GenomeDX. S.A.T. is a cofounder, previous consultant for and current employee of Strata Oncology. T.M.B. has research funding from Alliance Foundation Trials, Boehringer Ingelheim, Concept Therapeutics, Endocyte Inc., Janssen R&D, Medivation Inc./Astellas, oncoGenex, Sotio and Theraclone Sciences/OncoResponse. T.M.B. has received consulting fees from AbbVie, AstraZeneca, Astellas Pharma, Bayer, Boehringer Ingelheim, Clovis Oncology, GlaxoSmithKline, Janssen Biotech, Janssen Japan, Merck and Pfizer. T.M.B. holds stock in Salarius Pharmaceuticals. M.R. reports consulting and Speakers’ Bureau for Johnson & Johnson, research funding from Novartis, research support from Merck and Astellas/Medivation, and a provisional patent with UCLA on the development of small-molecule inhibitors of the androgen receptor N-terminal domain. J.J.A. has consulted for or held advisory roles at Astellas Pharma, Bayer and Janssen Biotech Inc. He has received research funding from Aragon Pharmaceuticals Inc., Astellas Pharma, Novartis, Zenith Epigenetics Ltd. and Gilead Sciences Inc. A.A. is a co-founder of Tango Therapeutics, Azkarra Therapeutics and Ovibio Corporation; is a consultant for SPARC, Bluestar, ProLynx, Earli, Cura, GenVivo and GSK; is a member of the SAB of Genentech and GLAdiator; receives grant/research support from SPARC and AstraZeneca; and holds patents on the use of PARP inhibitors held jointly with AstraZeneca, from which he has benefitted financially (and may do so in the future). F.Y.F. has consulted for Astellas, Bayer, BlueEarth Diagnostics, Celgene, Clovis, EMD Serono, Genentech, Janssen, Myovant, Ryovant and Sanofi, and is a co-founder and has an ownership stake in PFS Genomics. S.L.C. is in a leadership role at PFS Genomics. S.G.Z., S.L.C. and F.Y.F. have patent applications with Decipher Biosciences on molecular signatures in prostate cancer unrelated to this work. S.G.Z. and F.Y.F. have a patent application for a molecular signature in breast cancer unrelated to this work and licensed to PFS Genomics. S.G.Z. and F.Y.F. have patent applications with Celgene unrelated to this work.